NCT05295394View on ClinicalTrials.gov

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 22, 2019

Primary Completion Date

August 31, 2022

Study Completion Date

August 30, 2022

Conditions
HIV-1 Infection
Interventions
DRUG

Dolutegravir plus lamivudine

Dolutegravir 50 mg QD plus lamivudine 300 mg QD

Trial Locations (2)

C1202ABB

Fundacion huesped, CABA

S2000PBJ

CAICI, Rosario

Sponsors

Collaborators (1)

ViiV Healthcare
All Listed Sponsors
collaborator

ViiV Healthcare

INDUSTRY

lead

Pedro Cahn

OTHER

NCT05295394 - Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study | Biotech Hunter | Biotech Hunter